Zacks Research Predicts Lower Earnings for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO) – Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for Cooper Companies in a research note issued to investors on Thursday, March 27th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will earn $0.93 per share for the quarter, down from their prior estimate of $0.94. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, Q1 2027 earnings at $1.10 EPS and FY2027 earnings at $4.85 EPS.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million.

Several other brokerages have also commented on COO. BNP Paribas raised Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Stifel Nicolaus decreased their price target on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 7th. JPMorgan Chase & Co. dropped their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Robert W. Baird cut their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Finally, Wells Fargo & Company raised their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $81.27 on Monday. The stock’s 50-day simple moving average is $88.87 and its two-hundred day simple moving average is $96.83. Cooper Companies has a twelve month low of $77.05 and a twelve month high of $112.38. The firm has a market capitalization of $16.25 billion, a P/E ratio of 41.68, a P/E/G ratio of 2.25 and a beta of 1.02. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Institutional Investors Weigh In On Cooper Companies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Byrne Asset Management LLC bought a new position in Cooper Companies during the 4th quarter worth approximately $33,000. OFI Invest Asset Management bought a new stake in Cooper Companies during the 4th quarter valued at $34,000. New Age Alpha Advisors LLC purchased a new stake in Cooper Companies during the 4th quarter valued at $38,000. Covestor Ltd grew its holdings in Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Finally, West Financial Advisors LLC purchased a new position in shares of Cooper Companies in the fourth quarter valued at about $49,000. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.